More articles from Preclinical Probes for Oncology

You have access
Evaluation of dual-receptor targeted 68Ga-NGR-RGD in 8 different subcutaneous and orthotopic tumor models
Xiaoying Lv, Xiangming Song, Yu Long, Dexing Zeng, Yongkang Gai and Xiaoli Lan

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2883;
You have access
Characterization of Radiolabeled Peptides for PET Imaging of CD206 Positive Macrophages in Cancer
Candace Parker, Ahmad Bin Salam, Jesse Jaynes, Addison Hunt, Clayton Yates and Suzanne Lapi

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2871;
You have access
Development of 43Sc/47Sc-PSMA-617 as Theranostics for Prostate Cancer: Preliminary Cellular and Animal Studies
Jason Meier, Mohammed Bhuiyan, Hannah Zhang, Hsiu-Ming Tsai, Lucas Berens, Lara Leoni, Megan Mendez, Phillip Selman, Pavithra Kankanamalage, Thomas Brossard, Brittany Broder, Amy Renne, Matt Gott, John Greene, Jerry Nolen, Richard Freifelder, Walter Stadler, Ralph Weichselbaum, Chien-Min Kao, David Rotsch, Russell Szmulewitz and Chin-Tu Chen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2895;
You have access
Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices
Brett Vaughn, Darren Veach, Daniela Burnes Vargas, Shin Seo, Blesida Punzalan, Pat Zanzonico, Hong Xu, Hong-fen Guo, Guangbin Yang, Ouathek Ouerfelli, Nai-Kong Cheung, Steven Larson and Sarah Cheal

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2881;
You have access
TAM Targeted Imaging Agents Binding CD206 and Selective Blocking of Off Target Liver Localization
Jennifer Bartels, Solana Fernandez, Jeffrey Arnold, Grace O'Malley, David Ralph and Suzanne Lapi

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2862;
You have access
In vitro investigation of 225Ac-PSMA I&T and its decay products on PSMA expressing cancer cells
Alexander Wurzer, Samaa Saleh, Susanne Kossatz, Christof Seidl, Matthias Eiber, Kerstin Hürkamp, Wei Bo Li, Alfred Morgenstern, Frank Bruchertseifer, Calogero D'Alessandria and Wolfgang Weber

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2354;
You have access
Development of pH-responsive fatty acid-based albumin-binding ligands for cancer targeted imaging
Jeong-Seob Lee, SANGHEE LEE, Wooseung Lee, Miyeon Jeon, Jee-eun Hwang, Byung Chul Lee and Hyung-Jun Im

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2456;
You have access
Developing a new 18F-labeled peptide for PET imaging of GPC3 expression in hepatocellular carcinoma
Quan Chen, Xiaoyun Zhou, Juno Van Valkenburgh, Peter Conti and Kai Chen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2459;
You have access
Radiochemistry, biodistribution and imaging study of 161Tb and 155Tb labeled crown-αMSH for MC1R targeting theranostics
Luke Wharton, Scott McNeil, Gokce Engudar, Chengcheng Zhang, Michiel Van de Voorde, Maarten Ooms, Peter Kunz, Francois Benard, Valery Radchenko and Hua Yang

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2356;
You have access
PET imaging of a modified anti-PD-L1 probe 68Ga-BMS-986192 in immunocompetent mice and non-human primates
Huimin Zhou and Xiaohua Zhu

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2306;

Main menu

User menu

Search

More articles from Preclinical Probes for Oncology

Pages